The field of regenerative medicine is an up and coming new approach of targeting and treating diseases, it involves the repair and restoration of previously damaged tissues or organs in the body. The regenerative medicine market was worth $16bn in 2013 and industry analysts predict that this will leap to over $60bn by 2020. The more »

Molecular diagnostics is the use of molecular biology for medical testing and clinical applications. This discipline determines how genes and proteins interact in a cell. This partnering article reflects on the recent life science trends in the molecular diagnostics technology arena.

The bioinformatics partnering deal trend analysis 2009 to 2014 are reviewed in this article.

Monoclonal antibodies are developed to be very selective in targeting cells. This is why they have come to be an indispensable research tool in cancer treatment being able to specifically target tumor cells.

Recent life science trends has seen tremendous developments in new diagnostic and medical imaging techniques. Imaging tools such as CT scans, endoscopes, PET, SPECT, ultrasound and MRI are all showing promise and precise accuracy in diagnosing diseases like cancer, hospital care, cardiovascular, etc

Regenerative medicine has become increasingly popular in recent years, with the number of deals announced growing steadily

A recent market research analysis of monoclonal antibody partnering has shown a high interest in partnering deals involving monoclonal antibody technology in the past few years

Diagnostics are subject to numerous partnering deals every year. Here we provide a review of recent life science trends in deal making activity

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity.

Industry trends suggest that infectious vaccines research and development is an increasingly active component of healthcare business development. The last decade has witnessed a significant number of infectious vaccines partnering and M&A activity